PEPTOKING
EN

Trials to watch

Ongoing and recently finished clinical trials of the peptides in the catalogue. Phase, status, size and dates come from ClinicalTrials.gov and change as sponsors update the registry.

Primary completion is when the last participant is measured for the main outcome; results usually follow months later. Registry data checked Oct 2, 2026.

Results expected

  1. Phase 3Active, not recruiting

    STEP Young(opens the source in a new tab)

    A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

    Primary completion Oct 15, 2025210 participantsSponsor: Novo Nordisk A/SNCT05726227

  2. Phase 3Active, not recruiting

    Afamelanotide plus NB-UVB in vitiligo(opens the source in a new tab)

    A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

    Primary completion expected December 2025200 participantsSponsor: Clinuvel, Inc.NCT06109649

  3. Phase 2, Phase 3Active, not recruiting

    Intranasal oxytocin for chronic pain(opens the source in a new tab)

    Evaluating the Efficacy of Intranasal Oxytocin on Chronic Pain

    Primary completion expected Mar 31, 2026336 participantsSponsor: Memorial University of NewfoundlandNCT04903002

  4. Phase 2Recruiting

    Mazdutide in MASH(opens the source in a new tab)

    A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    Primary completion expected Apr 30, 2026165 participantsSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT06937749

  5. Phase 2Recruiting

    Vosoritide in idiopathic short stature(opens the source in a new tab)

    A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

    Primary completion expected June 2026100 participantsSponsor: BioMarin PharmaceuticalNCT06382155

  6. Phase 3Active, not recruiting

    SURMOUNT-ADOLESCENTS(opens the source in a new tab)

    A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

    Primary completion Jun 2, 2026160 participantsSponsor: Eli Lilly and CompanyNCT06075667

  7. Phase 3Active, not recruiting

    CANOPY-HCH-3(opens the source in a new tab)

    Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

    Primary completion expected Aug 1, 202680 participantsSponsor: BioMarin PharmaceuticalNCT06455059

  8. Phase 3Recruiting

    Mazdutide in hypertension(opens the source in a new tab)

    Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

    Primary completion expected Aug 1, 2026336 participantsSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT07469800

  9. Phase 3Active, not recruiting

    TRANSCEND-T2D-2(opens the source in a new tab)

    Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

    Primary completion Aug 27, 20261,250 participantsSponsor: Eli Lilly and CompanyNCT06260722

  10. Phase 2Active, not recruiting

    INFLAM MOTION(opens the source in a new tab)

    A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

    Primary completion Aug 31, 2026129 participantsSponsor: 4Moving BiotechNCT07225829

  11. Phase 2Active, not recruiting

    Mazdutide in heart failure(opens the source in a new tab)

    A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity

    Primary completion expected Sep 24, 2026141 participantsSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT06862908

  12. Phase 2Active, not recruiting

    Linaclotide in colorectal neoplasia(opens the source in a new tab)

    Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer

    Primary completion expected Sep 30, 2026150 participantsSponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityNCT03796884

  13. Phase 2Recruiting

    OxyTUTION(opens the source in a new tab)

    Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus

    Primary completion expected October 2026112 participantsSponsor: University Hospital, Basel, SwitzerlandNCT06036004

  14. Phase 2Not yet recruiting

    Sublingual oxytocin for PPH(opens the source in a new tab)

    Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage

    Primary completion expected Oct 30, 2026330 participantsSponsor: Insud PharmaNCT06968481

  15. Phase 3Active, not recruiting

    SURPASS-T1D-1(opens the source in a new tab)

    A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

    Primary completion expected November 2026905 participantsSponsor: Eli Lilly and CompanyNCT06914895

  16. Phase 3Active, not recruiting

    TRIUMPH-5(opens the source in a new tab)

    A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

    Primary completion expected November 2026800 participantsSponsor: Eli Lilly and CompanyNCT06662383

  17. Phase 3Active, not recruiting

    OVELIA(opens the source in a new tab)

    Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

    Primary completion expected Nov 30, 2026250 participantsSponsor: Tolmar Inc.NCT04906395

  18. Phase 2Active, not recruiting

    LOCITT(opens the source in a new tab)

    The Long COVID Treatment Trial

    Primary completion expected December 20261,000 participantsSponsor: Scripps Translational Science InstituteNCT07128082

  19. Phase 3Active, not recruiting

    GLORY-3(opens the source in a new tab)

    A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）

    Primary completion expected Dec 31, 2026479 participantsSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT06884293

  20. Phase 2Active, not recruiting

    FAST-Healing(opens the source in a new tab)

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

    Primary completion expected February 202796 participantsSponsor: Hospital for Special Surgery, New YorkNCT03841058

  21. Phase 2, Phase 3Recruiting

    Thy-α1 for RIF(opens the source in a new tab)

    Thymosin-α1 for Recurrent Implantation Failure

    Primary completion expected February 2027136 participantsSponsor: Fakih IVF Fertility CenterNCT07675980

  22. Phase 3Active, not recruiting

    Teduglutide in Chinese adults with SBS(opens the source in a new tab)

    A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome

    Primary completion expected Feb 10, 202713 participantsSponsor: TakedaNCT06973304

  23. Phase 2Recruiting

    INHALE-1st(opens the source in a new tab)

    INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

    Primary completion expected March 2027100 participantsSponsor: Mannkind CorporationNCT07224321

  24. Phase 3Recruiting

    Congenital hypothalamic obesity(opens the source in a new tab)

    A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

    Primary completion expected Mar 13, 202739 participantsSponsor: Rhythm Pharmaceuticals, Inc.NCT06760546

  25. Phase 3Recruiting

    Liraglutide for delirium after surgery(opens the source in a new tab)

    Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

    Primary completion expected Mar 31, 2027260 participantsSponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT06361238

  26. Phase 3Recruiting

    Thymosin alpha-1 in colorectal cancer(opens the source in a new tab)

    Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

    Primary completion expected Mar 31, 20272,500 participantsSponsor: Fudan UniversityNCT05086614

  27. Phase 3Not yet recruiting

    Oral insulin ORMD-0801 in T2D(opens the source in a new tab)

    A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.

    Primary completion expected Apr 25, 2027300 participantsSponsor: Oramed, Ltd.NCT06731075

  28. Phase 3Not yet recruiting

    Abaloparatide vs teriparatide in China(opens the source in a new tab)

    To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

    Primary completion expected May 2027282 participantsSponsor: Qilu Pharmaceutical Co., Ltd.NCT06898060

  29. Phase 3Recruiting

    GLORY-OSA(opens the source in a new tab)

    A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2

    Primary completion expected May 7, 2027260 participantsSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT06931028

  30. Phase 3Active, not recruiting

    RENEW 1(opens the source in a new tab)

    Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

    Primary completion expected May 11, 2027300 participantsSponsor: Novo Nordisk A/SNCT07220642

  31. Phase 3Active, not recruiting

    RENEW 2(opens the source in a new tab)

    Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

    Primary completion expected May 12, 2027330 participantsSponsor: Novo Nordisk A/SNCT07220759

  32. Phase 3Active, not recruiting

    ReNEW(opens the source in a new tab)

    ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

    Primary completion expected August 2027313 participantsSponsor: Stealth BioTherapeutics Inc.NCT06373731

  33. Phase 3Active, not recruiting

    Adjuvant leuprorelin after prostatectomy(opens the source in a new tab)

    Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

    Primary completion expected September 2027700 participantsSponsor: UNICANCERNCT01442246

  34. Phase 3Recruiting

    OPIC(opens the source in a new tab)

    Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening

    Primary completion expected September 20271,494 participantsSponsor: University Hospital, ToursNCT04949633

  35. Phase 3Active, not recruiting

    TRIUMPH-7(opens the source in a new tab)

    A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

    Primary completion expected September 2027586 participantsSponsor: Eli Lilly and CompanyNCT07035093

  36. Phase 3Active, not recruiting

    REDEFINE 3(opens the source in a new tab)

    REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

    Primary completion expected Sep 1, 20277,101 participantsSponsor: Novo Nordisk A/SNCT05669755

  37. Phase 2Recruiting

    TAB(opens the source in a new tab)

    Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

    Primary completion expected Sep 30, 2027310 participantsSponsor: T. John Winhusen, PhDNCT06651177

  38. Phase 3Active, not recruiting

    SURMOUNT-MMO(opens the source in a new tab)

    A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

    Primary completion expected October 202715,374 participantsSponsor: Eli Lilly and CompanyNCT05556512

  39. Phase 3Active, not recruiting

    ADOPT(opens the source in a new tab)

    Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy

    Primary completion expected Oct 21, 2027280 participantsSponsor: University Medical Center GroningenNCT04302454

  40. Phase 3Recruiting

    GLORY-YOUNG(opens the source in a new tab)

    A Study of IBI362 in Chinese Adolescents With Obesity or Overweight

    Primary completion expected Oct 31, 2027180 participantsSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT07255209

  41. Phase 3Active, not recruiting

    FOCUS(opens the source in a new tab)

    A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

    Primary completion expected Nov 7, 20271,500 participantsSponsor: Novo Nordisk A/SNCT03811561

  42. Phase 2Not yet recruiting

    ARTIST-CKD(opens the source in a new tab)

    Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease

    Primary completion expected Nov 30, 2027120 participantsSponsor: University Medical Center GroningenNCT07206290

  43. Phase 3Recruiting

    AWARD-PEDS PLUS(opens the source in a new tab)

    A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

    Primary completion expected December 202755 participantsSponsor: Eli Lilly and CompanyNCT06739122

  44. Phase 3Recruiting

    Survodutide in type 2 diabetes(opens the source in a new tab)

    A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Primary completion expected Jan 17, 2028600 participantsSponsor: Boehringer IngelheimNCT07754461

  45. Phase 2Recruiting

    TRIUMPH (tesamorelin)(opens the source in a new tab)

    Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

    Primary completion expected Jun 16, 2028100 participantsSponsor: Massachusetts General HospitalNCT06554717

  46. Phase 3Recruiting

    AMAZE 9(opens the source in a new tab)

    AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

    Primary completion expected Jun 27, 2028950 participantsSponsor: Novo Nordisk A/SNCT07720271

  47. Phase 2Recruiting

    Vosoritide in infant hypochondroplasia(opens the source in a new tab)

    A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months

    Primary completion expected Jun 30, 202860 participantsSponsor: BioMarin PharmaceuticalNCT07126262

  48. Phase 3Recruiting

    AMAZE 3(opens the source in a new tab)

    AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

    Primary completion expected Jul 12, 2028300 participantsSponsor: Novo Nordisk A/SNCT07571005

  49. Phase 3Not yet recruiting

    SYNCHRONIZE-HERA(opens the source in a new tab)

    SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

    Primary completion expected Jul 26, 2028600 participantsSponsor: Boehringer IngelheimNCT07850050

  50. Phase 3Recruiting

    AMBITION 7(opens the source in a new tab)

    AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

    Primary completion expected Jul 31, 20281,778 participantsSponsor: Novo Nordisk A/SNCT07797335

  51. Phase 3Recruiting

    AMAZE 2(opens the source in a new tab)

    AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

    Primary completion expected Aug 7, 2028630 participantsSponsor: Novo Nordisk A/SNCT07533175

  52. Phase 3Recruiting

    AMAZE 5(opens the source in a new tab)

    A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

    Primary completion expected Aug 14, 2028400 participantsSponsor: Novo Nordisk A/SNCT07481630

  53. Phase 2Recruiting

    CBCT-OT RCT(opens the source in a new tab)

    Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD

    Primary completion expected Sep 30, 2028240 participantsSponsor: VA Office of Research and DevelopmentNCT06194851

  54. Phase 3Recruiting

    AMAZE 7(opens the source in a new tab)

    A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

    Primary completion expected Oct 10, 2028650 participantsSponsor: Novo Nordisk A/SNCT07668414

  55. Phase 2, Phase 3Recruiting

    Pulsatile GnRH in Down syndrome(opens the source in a new tab)

    GnRH Therapy on Cognition in Down Syndrome

    Primary completion expected December 202856 participantsSponsor: Nelly PitteloudNCT04390646

  56. Phase 3Not yet recruiting

    AMAZE 8(opens the source in a new tab)

    AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

    Primary completion expected Dec 12, 20281,000 participantsSponsor: Novo Nordisk A/SNCT07400107

Finished or stopped

  1. Phase 2Completed

    Thymosin alpha-1 in lung cancer(opens the source in a new tab)

    The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

    Primary completion Jun 30, 2026114 participantsSponsor: Sun Yat-sen UniversityNCT06139419

  2. Phase 3Completed

    TRIUMPH-2(opens the source in a new tab)

    A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

    Primary completion Jun 16, 20261,152 participantsSponsor: Eli Lilly and CompanyNCT05929079

  3. Phase 3Completed

    SYNCHRONIZE-CVOT(opens the source in a new tab)

    A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

    Primary completion Jun 1, 20265,531 participantsSponsor: Boehringer IngelheimNCT06077864

  4. Phase 3Completed

    TRIUMPH-3(opens the source in a new tab)

    A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

    Primary completion Apr 16, 20261,946 participantsSponsor: Eli Lilly and CompanyNCT05882045

  5. Phase 2Completed

    COPE+OT(opens the source in a new tab)

    Oxytocin to Enhance Integrated Treatment for AUD and PTSD

    Primary completion Apr 13, 2026175 participantsSponsor: Medical University of South CarolinaNCT04523922

  6. Phase 3Completed

    TRIUMPH-1(opens the source in a new tab)

    A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

    Primary completion Apr 6, 20262,335 participantsSponsor: Eli Lilly and CompanyNCT05929066

  7. Phase 2Completed

    Mazdutide in alcohol use disorder(opens the source in a new tab)

    A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

    Primary completion Mar 19, 2026308 participantsSponsor: Eli Lilly and CompanyNCT06817356

  8. Phase 3Completed

    TRANSCEND-T2D-1(opens the source in a new tab)

    Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

    Primary completion Jan 22, 2026537 participantsSponsor: Eli Lilly and CompanyNCT06354660

  9. Phase 3Completed

    TOGETHER-PsO(opens the source in a new tab)

    Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

    Primary completion Jan 8, 2026281 participantsSponsor: Eli Lilly and CompanyNCT06588283

  10. Phase 3Completed

    EMANATE(opens the source in a new tab)

    EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

    Primary completion Dec 22, 2025296 participantsSponsor: Rhythm Pharmaceuticals, Inc.NCT05093634

  11. Phase 3Completed

    SYNCHRONIZE-2(opens the source in a new tab)

    A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

    Primary completion Dec 12, 2025755 participantsSponsor: Boehringer IngelheimNCT06066528

  12. Phase 3Completed

    CagriSema vs tirzepatide in obesity(opens the source in a new tab)

    A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

    Primary completion Dec 8, 2025809 participantsSponsor: Novo Nordisk A/SNCT06131437

  13. Phase 3Completed

    Leuprolide mesylate in early puberty(opens the source in a new tab)

    Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

    Primary completion Dec 7, 202594 participantsSponsor: Foresee Pharmaceuticals Co., Ltd.NCT05493709

  14. Phase 3Completed

    SYNCHRONIZE-1(opens the source in a new tab)

    A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

    Primary completion Dec 2, 2025726 participantsSponsor: Boehringer IngelheimNCT06066515

  15. Phase 3Completed

    REIMAGINE 2(opens the source in a new tab)

    A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

    Primary completion Nov 19, 20252,734 participantsSponsor: Novo Nordisk A/SNCT06065540

  16. Phase 3Completed

    TRIUMPH-4(opens the source in a new tab)

    A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

    Primary completion Nov 14, 2025445 participantsSponsor: Eli Lilly and CompanyNCT05931367

  17. Phase 2Completed

    Exenatide for smoking cessation(opens the source in a new tab)

    Exenatide for Smoking Cessation and Prevention of Weight Gain

    Primary completion Nov 7, 2025140 participantsSponsor: The University of Texas Health Science Center, HoustonNCT05610800

  18. Phase 3Completed

    SYNCHRONIZE-MASLD(opens the source in a new tab)

    A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

    Primary completion Oct 9, 2025218 participantsSponsor: Boehringer IngelheimNCT06309992

  19. Phase 2Completed

    Amycretin in type 2 diabetes(opens the source in a new tab)

    A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

    Primary completion Oct 1, 2025448 participantsSponsor: Novo Nordisk A/SNCT06542874

  20. Phase 3Completed

    DREAMS-3(opens the source in a new tab)

    A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

    Primary completion Sep 17, 2025349 participantsSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT06184568

  21. Phase 3Completed

    EVOKE(opens the source in a new tab)

    A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

    Primary completion Sep 16, 20251,840 participantsSponsor: Novo Nordisk A/SNCT04777396

  22. Phase 3Completed

    EVOKE Plus(opens the source in a new tab)

    A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

    Primary completion Sep 15, 20251,840 participantsSponsor: Novo Nordisk A/SNCT04777409

  23. Phase 3CompletedResults posted

    Linaclotide in constipation, ages 2 to 5(opens the source in a new tab)

    A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

    Primary completion Sep 2, 2025123 participantsSponsor: AbbVieNCT05652205

  24. Phase 2Completed

    SEMALCO(opens the source in a new tab)

    Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

    Primary completion Jul 31, 2025108 participantsSponsor: Psychiatric Centre RigshospitaletNCT05895643